Health Catalyst, Inc. (NASDAQ: HCAT) Stock Competitors & Peer Comparison

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, GEHC has a market cap of 32.9B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while GEHC trades at $72.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas GEHC's P/E ratio is 16.00. In terms of profitability, HCAT's ROE is -1.30%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, HCAT is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check GEHC's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas GEHCV's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, HCAT is less volatile compared to GEHCV. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check GEHCV's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, BTSG has a market cap of 12.1B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while BTSG trades at $61.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas BTSG's P/E ratio is 49.56. In terms of profitability, HCAT's ROE is -1.30%, compared to BTSG's ROE of +0.15%. Regarding short-term risk, HCAT is more volatile compared to BTSG. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check BTSG's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, TEM has a market cap of 9.6B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while TEM trades at $55.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas TEM's P/E ratio is -110.12. In terms of profitability, HCAT's ROE is -1.30%, compared to TEM's ROE of -0.55%. Regarding short-term risk, HCAT is less volatile compared to TEM. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check TEM's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas SGFY's P/E ratio is 70.91. In terms of profitability, HCAT's ROE is -1.30%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, HCAT is more volatile compared to SGFY. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SGFY's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, HQY has a market cap of 8.9B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while HQY trades at $106.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas HQY's P/E ratio is 24.95. In terms of profitability, HCAT's ROE is -1.30%, compared to HQY's ROE of +0.11%. Regarding short-term risk, HCAT is more volatile compared to HQY. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check HQY's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, TXG has a market cap of 7.4B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while TXG trades at $58.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas TXG's P/E ratio is -344.53. In terms of profitability, HCAT's ROE is -1.30%, compared to TXG's ROE of -0.09%. Regarding short-term risk, HCAT is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check TXG's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, HNGE has a market cap of 7.1B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while HNGE trades at $91.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas HNGE's P/E ratio is 48.99. In terms of profitability, HCAT's ROE is -1.30%, compared to HNGE's ROE of +0.30%. Regarding short-term risk, HCAT is more volatile compared to HNGE. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check HNGE's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas RCM's P/E ratio is -102.21. In terms of profitability, HCAT's ROE is -1.30%, compared to RCM's ROE of +0.00%. Regarding short-term risk, HCAT is more volatile compared to RCM. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check RCM's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, DOCS has a market cap of 4.8B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while DOCS trades at $25.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas DOCS's P/E ratio is 16.82. In terms of profitability, HCAT's ROE is -1.30%, compared to DOCS's ROE of +0.17%. Regarding short-term risk, HCAT is less volatile compared to DOCS. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check DOCS's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, WAY has a market cap of 4.7B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while WAY trades at $24.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas WAY's P/E ratio is 16.36. In terms of profitability, HCAT's ROE is -1.30%, compared to WAY's ROE of +0.04%. Regarding short-term risk, HCAT is more volatile compared to WAY. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check WAY's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas ONEM's P/E ratio is -7.77. In terms of profitability, HCAT's ROE is -1.30%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, HCAT is more volatile compared to ONEM. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check ONEM's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, PRVA has a market cap of 2.8B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while PRVA trades at $22.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas PRVA's P/E ratio is 106.52. In terms of profitability, HCAT's ROE is -1.30%, compared to PRVA's ROE of +0.00%. Regarding short-term risk, HCAT is more volatile compared to PRVA. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check PRVA's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, HTFL has a market cap of 2.5B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while HTFL trades at $29.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas HTFL's P/E ratio is -14.60. In terms of profitability, HCAT's ROE is -1.30%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, HCAT is less volatile compared to HTFL. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check HTFL's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, WGS has a market cap of 2.3B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while WGS trades at $77.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas WGS's P/E ratio is 216.33. In terms of profitability, HCAT's ROE is -1.30%, compared to WGS's ROE of -0.39%. Regarding short-term risk, HCAT is more volatile compared to WGS. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check WGS's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, PGNY has a market cap of 2.2B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while PGNY trades at $27.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas PGNY's P/E ratio is 20.18. In terms of profitability, HCAT's ROE is -1.30%, compared to PGNY's ROE of +0.16%. Regarding short-term risk, HCAT is more volatile compared to PGNY. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check PGNY's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas NXGN's P/E ratio is -266.00. In terms of profitability, HCAT's ROE is -1.30%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, HCAT is more volatile compared to NXGN. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check NXGN's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, OMDA has a market cap of 1.5B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while OMDA trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas OMDA's P/E ratio is 357.00. In terms of profitability, HCAT's ROE is -1.30%, compared to OMDA's ROE of +0.02%. Regarding short-term risk, HCAT is more volatile compared to OMDA. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check OMDA's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas AGTI's P/E ratio is -71.79. In terms of profitability, HCAT's ROE is -1.30%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, HCAT is more volatile compared to AGTI. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check AGTI's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, TDOC has a market cap of 1.3B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while TDOC trades at $7.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas TDOC's P/E ratio is -7.86. In terms of profitability, HCAT's ROE is -1.30%, compared to TDOC's ROE of -0.13%. Regarding short-term risk, HCAT is more volatile compared to TDOC. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check TDOC's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, GDRX has a market cap of 1.3B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while GDRX trades at $3.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas GDRX's P/E ratio is 11.44. In terms of profitability, HCAT's ROE is -1.30%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, HCAT is less volatile compared to GDRX. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check GDRX's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, CERT has a market cap of 1.3B. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while CERT trades at $8.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas CERT's P/E ratio is 20.18. In terms of profitability, HCAT's ROE is -1.30%, compared to CERT's ROE of -0.07%. Regarding short-term risk, HCAT is more volatile compared to CERT. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CERT's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, HSTM has a market cap of 858.1M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while HSTM trades at $29.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas HSTM's P/E ratio is 36.26. In terms of profitability, HCAT's ROE is -1.30%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, HCAT is more volatile compared to HSTM. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check HSTM's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while CCLDO trades at $27.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas CCLDO's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, HCAT is more volatile compared to CCLDO. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CCLDO's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, PHR has a market cap of 768.3M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while PHR trades at $12.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas PHR's P/E ratio is 44.39. In terms of profitability, HCAT's ROE is -1.30%, compared to PHR's ROE of +0.03%. Regarding short-term risk, HCAT is more volatile compared to PHR. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check PHR's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to MPLN-WT's ROE of +1.40%. Regarding short-term risk, HCAT is less volatile compared to MPLN-WT. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check MPLN-WT's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, CTEV has a market cap of 579.2M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while CTEV trades at $34.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas CTEV's P/E ratio is -2.61. In terms of profitability, HCAT's ROE is -1.30%, compared to CTEV's ROE of +1.40%. Regarding short-term risk, HCAT is less volatile compared to CTEV. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check CTEV's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas ACCD's P/E ratio is -3.08. In terms of profitability, HCAT's ROE is -1.30%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, HCAT is more volatile compared to ACCD. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check ACCD's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, SOPH has a market cap of 534.7M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while SOPH trades at $7.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas SOPH's P/E ratio is -6.91. In terms of profitability, HCAT's ROE is -1.30%, compared to SOPH's ROE of -1.37%. Regarding short-term risk, HCAT is more volatile compared to SOPH. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SOPH's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas SHCR's P/E ratio is -3.76. In terms of profitability, HCAT's ROE is -1.30%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, HCAT is more volatile compared to SHCR. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SHCR's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, NRC has a market cap of 471M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while NRC trades at $20.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas NRC's P/E ratio is 25.49. In terms of profitability, HCAT's ROE is -1.30%, compared to NRC's ROE of +0.48%. Regarding short-term risk, HCAT is more volatile compared to NRC. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check NRC's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, EVH has a market cap of 443.2M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while EVH trades at $3.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas EVH's P/E ratio is 30.31. In terms of profitability, HCAT's ROE is -1.30%, compared to EVH's ROE of -0.99%. Regarding short-term risk, HCAT is less volatile compared to EVH. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check EVH's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas SLGC's P/E ratio is -3.04. In terms of profitability, HCAT's ROE is -1.30%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, HCAT is less volatile compared to SLGC. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check SLGC's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, HCAT's ROE is -1.30%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, HCAT is less volatile compared to SLGCW. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check SLGCW's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, TBRG has a market cap of 393.6M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while TBRG trades at $26.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas TBRG's P/E ratio is 9.37. In terms of profitability, HCAT's ROE is -1.30%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, HCAT is more volatile compared to TBRG. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check TBRG's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas MPLN's P/E ratio is -0.23. In terms of profitability, HCAT's ROE is -1.30%, compared to MPLN's ROE of +1.40%. Regarding short-term risk, HCAT is less volatile compared to MPLN. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check MPLN's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, SY has a market cap of 297.8M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while SY trades at $2.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas SY's P/E ratio is -6.88. In terms of profitability, HCAT's ROE is -1.30%, compared to SY's ROE of -0.16%. Regarding short-term risk, HCAT is less volatile compared to SY. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check SY's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas TRHC's P/E ratio is -4.27. In terms of profitability, HCAT's ROE is -1.30%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, HCAT is more volatile compared to TRHC. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check TRHC's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas SMFR's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to SMFR's ROE of -0.39%. Regarding short-term risk, HCAT is less volatile compared to SMFR. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check SMFR's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, SPOK has a market cap of 236.6M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while SPOK trades at $11.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas SPOK's P/E ratio is 18.88. In terms of profitability, HCAT's ROE is -1.30%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, HCAT is more volatile compared to SPOK. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SPOK's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, AMWL has a market cap of 228.6M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while AMWL trades at $13.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas AMWL's P/E ratio is -3.04. In terms of profitability, HCAT's ROE is -1.30%, compared to AMWL's ROE of -0.33%. Regarding short-term risk, HCAT is more volatile compared to AMWL. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check AMWL's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas CPSI's P/E ratio is -183.80. In terms of profitability, HCAT's ROE is -1.30%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, HCAT is less volatile compared to CPSI. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check CPSI's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, OPRX has a market cap of 128.7M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while OPRX trades at $6.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas OPRX's P/E ratio is 6.29. In terms of profitability, HCAT's ROE is -1.30%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, HCAT is more volatile compared to OPRX. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check OPRX's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas AUGX's P/E ratio is -4.99. In terms of profitability, HCAT's ROE is -1.30%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, HCAT is more volatile compared to AUGX. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check AUGX's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, CCLD has a market cap of 102.4M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while CCLD trades at $2.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas CCLD's P/E ratio is 9.27. In terms of profitability, HCAT's ROE is -1.30%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, HCAT is less volatile compared to CCLD. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check CCLD's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, WORX has a market cap of 88M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while WORX trades at $5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas WORX's P/E ratio is -6.40. In terms of profitability, HCAT's ROE is -1.30%, compared to WORX's ROE of -0.65%. Regarding short-term risk, HCAT is less volatile compared to WORX. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check WORX's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, DH has a market cap of 73.7M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while DH trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas DH's P/E ratio is 2.69. In terms of profitability, HCAT's ROE is -1.30%, compared to DH's ROE of -0.67%. Regarding short-term risk, HCAT is more volatile compared to DH. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check DH's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while FORA trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas FORA's P/E ratio is -24.11. In terms of profitability, HCAT's ROE is -1.30%, compared to FORA's ROE of -0.17%. Regarding short-term risk, HCAT is more volatile compared to FORA. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check FORA's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas CCLDP's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, HCAT is more volatile compared to CCLDP. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CCLDP's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, ONMD has a market cap of 37.6M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while ONMD trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas ONMD's P/E ratio is -4.40. In terms of profitability, HCAT's ROE is -1.30%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, HCAT is less volatile compared to ONMD. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check ONMD's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas SNCE's P/E ratio is -0.27. In terms of profitability, HCAT's ROE is -1.30%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, HCAT is more volatile compared to SNCE. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SNCE's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas AKLI's P/E ratio is -0.71. In terms of profitability, HCAT's ROE is -1.30%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, HCAT is more volatile compared to AKLI. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check AKLI's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas SHLT's P/E ratio is -3.87. In terms of profitability, HCAT's ROE is -1.30%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, HCAT is more volatile compared to SHLT. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SHLT's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, ONMDW has a market cap of 33.4M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while ONMDW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas ONMDW's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, HCAT is more volatile compared to ONMDW. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check ONMDW's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, HCAT's ROE is -1.30%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, HCAT is more volatile compared to SHCRW. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check SHCRW's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas STRM's P/E ratio is -2.40. In terms of profitability, HCAT's ROE is -1.30%, compared to STRM's ROE of -0.65%. Regarding short-term risk, HCAT is more volatile compared to STRM. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check STRM's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas RNLX's P/E ratio is -0.33. In terms of profitability, HCAT's ROE is -1.30%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, HCAT is less volatile compared to RNLX. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check RNLX's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas LIFW's P/E ratio is -0.02. In terms of profitability, HCAT's ROE is -1.30%, compared to LIFW's ROE of +1.56%. Regarding short-term risk, HCAT is more volatile compared to LIFW. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check LIFW's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas BBLN's P/E ratio is -0.04. In terms of profitability, HCAT's ROE is -1.30%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, HCAT is less volatile compared to BBLN. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check BBLN's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, BEATW has a market cap of 11.7M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while BEATW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas BEATW's P/E ratio is -0.03. In terms of profitability, HCAT's ROE is -1.30%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, HCAT is less volatile compared to BEATW. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check BEATW's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, MGRX has a market cap of 10.1M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while MGRX trades at $0.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas MGRX's P/E ratio is -0.44. In terms of profitability, HCAT's ROE is -1.30%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, HCAT is less volatile compared to MGRX. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check MGRX's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas ETAO's P/E ratio is -0.01. In terms of profitability, HCAT's ROE is -1.30%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, HCAT is less volatile compared to ETAO. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check ETAO's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, BFRG has a market cap of 6.8M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while BFRG trades at $0.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas BFRG's P/E ratio is -1.07. In terms of profitability, HCAT's ROE is -1.30%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, HCAT is less volatile compared to BFRG. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check BFRG's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, SCNX has a market cap of 6.4M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while SCNX trades at $0.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas SCNX's P/E ratio is -0.17. In terms of profitability, HCAT's ROE is -1.30%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, HCAT is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check SCNX's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while UPH-WT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, HCAT is less volatile compared to UPH-WT. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check UPH-WT's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas UPH's P/E ratio is -0.07. In terms of profitability, HCAT's ROE is -1.30%, compared to UPH's ROE of -1.05%. Regarding short-term risk, HCAT is less volatile compared to UPH. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check UPH's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas PEARW's P/E ratio is -0.00. In terms of profitability, HCAT's ROE is -1.30%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, HCAT is less volatile compared to PEARW. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check PEARW's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas PEAR's P/E ratio is -0.08. In terms of profitability, HCAT's ROE is -1.30%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, HCAT is less volatile compared to PEAR. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check PEAR's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while OTRK trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas OTRK's P/E ratio is -0.02. In terms of profitability, HCAT's ROE is -1.30%, compared to OTRK's ROE of -2.11%. Regarding short-term risk, HCAT is more volatile compared to OTRK. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check OTRK's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas CMAX's P/E ratio is -0.00. In terms of profitability, HCAT's ROE is -1.30%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, HCAT is more volatile compared to CMAX. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CMAX's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, HCTI has a market cap of 1.4M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while HCTI trades at $1.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas HCTI's P/E ratio is -0.16. In terms of profitability, HCAT's ROE is -1.30%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, HCAT is more volatile compared to HCTI. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check HCTI's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, VSEEW has a market cap of 1.4M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while VSEEW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas VSEEW's P/E ratio is -0.04. In terms of profitability, HCAT's ROE is -1.30%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, HCAT is less volatile compared to VSEEW. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check VSEEW's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, ACON has a market cap of 1.3M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while ACON trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas ACON's P/E ratio is -0.27. In terms of profitability, HCAT's ROE is -1.30%, compared to ACON's ROE of -0.59%. Regarding short-term risk, HCAT is more volatile compared to ACON. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check ACON's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to LIFWZ's ROE of +1.56%. Regarding short-term risk, HCAT is more volatile compared to LIFWZ. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check LIFWZ's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, EUDAW has a market cap of 1.1M. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while EUDAW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas EUDAW's P/E ratio is 0.04. In terms of profitability, HCAT's ROE is -1.30%, compared to EUDAW's ROE of +1.20%. Regarding short-term risk, HCAT is more volatile compared to EUDAW. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check EUDAW's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, VSEE has a market cap of 816.5K. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while VSEE trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas VSEE's P/E ratio is -0.10. In terms of profitability, HCAT's ROE is -1.30%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, HCAT is less volatile compared to VSEE. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check VSEE's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while MSPRZ trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to MSPRZ's ROE of +1.56%. Regarding short-term risk, HCAT is less volatile compared to MSPRZ. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check MSPRZ's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas KERN's P/E ratio is -0.01. In terms of profitability, HCAT's ROE is -1.30%, compared to KERN's ROE of -0.20%. Regarding short-term risk, HCAT is less volatile compared to KERN. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check KERN's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas KERNW's P/E ratio is -0.00. In terms of profitability, HCAT's ROE is -1.30%, compared to KERNW's ROE of -0.20%. Regarding short-term risk, HCAT is less volatile compared to KERNW. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check KERNW's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas LIFWW's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to LIFWW's ROE of +1.56%. Regarding short-term risk, HCAT is more volatile compared to LIFWW. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check LIFWW's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, ZCMD has a market cap of 39.1K. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while ZCMD trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas ZCMD's P/E ratio is -0.04. In terms of profitability, HCAT's ROE is -1.30%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, HCAT is less volatile compared to ZCMD. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check ZCMD's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas CMAXW's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, HCAT is more volatile compared to CMAXW. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CMAXW's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, ACONW has a market cap of 13.2K. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while ACONW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas ACONW's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to ACONW's ROE of -0.59%. Regarding short-term risk, HCAT is more volatile compared to ACONW. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check ACONW's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while WGSWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, HCAT's ROE is -1.30%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, HCAT is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check WGSWW's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while CHNG trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas CHNG's P/E ratio is -152.72. In terms of profitability, HCAT's ROE is -1.30%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, HCAT is more volatile compared to CHNG. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CHNG's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while CNVY trades at $10.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas CNVY's P/E ratio is -71.50. In terms of profitability, HCAT's ROE is -1.30%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, HCAT is more volatile compared to CNVY. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CNVY's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while MTBC trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas MTBC's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to MTBC's ROE of +0.19%. Regarding short-term risk, HCAT is less volatile compared to MTBC. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check MTBC's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, KURIU has a market cap of 0. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while KURIU trades at $9.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas KURIU's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to KURIU's ROE of +1.06%. Regarding short-term risk, HCAT is less volatile compared to KURIU. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check KURIU's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while MSPRV trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas MSPRV's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to MSPRV's ROE of N/A. Regarding short-term risk, HCAT is less volatile compared to MSPRV. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check MSPRV's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while MTBCP trades at $26.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas MTBCP's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, HCAT is more volatile compared to MTBCP. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check MTBCP's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while SMFRW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas SMFRW's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to SMFRW's ROE of -0.39%. Regarding short-term risk, HCAT is less volatile compared to SMFRW. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check SMFRW's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, IMS has a market cap of 0. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while IMS trades at $31.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas IMS's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to IMS's ROE of +0.27%. Regarding short-term risk, HCAT is more volatile compared to IMS. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check IMS's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while CHNGU trades at $73.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas CHNGU's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, HCAT is more volatile compared to CHNGU. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CHNGU's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, NAVA has a market cap of 0. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while NAVA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas NAVA's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, HCAT is not fully comparable compared to NAVA. This indicates unavailable risk data in terms of short-term price fluctuations for HCAT.Check NAVA's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, NH has a market cap of 0. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while NH trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas NH's P/E ratio is -0.12. In terms of profitability, HCAT's ROE is -1.30%, compared to NH's ROE of +0.35%. Regarding short-term risk, HCAT is less volatile compared to NH. This indicates lower risk in terms of short-term price fluctuations for HCAT.Check NH's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, AFFX has a market cap of 0. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while AFFX trades at $14.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas AFFX's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, HCAT is more volatile compared to AFFX. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check AFFX's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, CERN has a market cap of 0. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while CERN trades at $94.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas CERN's P/E ratio is 55.84. In terms of profitability, HCAT's ROE is -1.30%, compared to CERN's ROE of +0.14%. Regarding short-term risk, HCAT is more volatile compared to CERN. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CERN's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, CSLT has a market cap of 0. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while CSLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas CSLT's P/E ratio is -37.27. In terms of profitability, HCAT's ROE is -1.30%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, HCAT is more volatile compared to CSLT. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check CSLT's competition here

Health Catalyst, Inc. (NASDAQ: HCAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCAT stands at 127.1M. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, HCAT is priced at $1.72 on the NASDAQ, while MTBCO trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCAT currently has a P/E ratio of 8.60, whereas MTBCO's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.30%, compared to MTBCO's ROE of +0.17%. Regarding short-term risk, HCAT is more volatile compared to MTBCO. This indicates higher risk in terms of short-term price fluctuations for HCAT.Check MTBCO's competition here